Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Brennan
TD
Daniel Brennan
Wall Street Analyst
★★☆☆☆
#2165
on 13Foresight · ranked by our own returns
43%
Success Rate
-0.9%
Average Return
19 of 44 calls profitable · -196.7% vs benchmark
📈 Across the calls we could measure, roughly 43% of Daniel Brennan's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

147 Buy 71 Hold 0 Sell
Daniel's Stock Coverage 41 ratings · 2026-06-21
Company Date Position Consensus Price Target 1-Yr Return
RVTY
Revvity
Jun 18, 2026 BUY Buy
+5.2% avg upside
23 analysts
$120.00
20.06% Upside
+0.0%
TEM
Tempus AI, Inc. Class A
Jun 01, 2026 BUY Strong Buy
+33.4% avg upside
19 analysts
$68.00
33.67% Upside
-4.2%
GRAL
GRAIL Inc
May 27, 2026 BUY Buy
+2.9% avg upside
8 analysts
-18.4%
A
Agilent
May 27, 2026 BUY Strong Buy
+3.8% avg upside
32 analysts
$155.00
22.02% Upside
+7.3%
TMO
Thermo Fisher
May 20, 2026 BUY Strong Buy
+26.8% avg upside
38 analysts
+2.3%
MDXH
MDxHealth
May 14, 2026 BUY Strong Buy
+1070.8% avg upside
8 analysts
$1.50
176.33% Upside
-44.9%
ALMR
Alamar Biosciences, Inc.
May 12, 2026 BUY Strong Buy
+36.6% avg upside
5 analysts
$30.00
36.64% Upside
·
XGN
Exagen
May 11, 2026 BUY Strong Buy
+159.4% avg upside
10 analysts
$8.00
76.22% Upside
-8.5%
CAI
Caris Life Sciences, Inc.
May 08, 2026 BUY Strong Buy
+54.5% avg upside
20 analysts
$31.00
67.74% Upside
+2.1%
PSNL
Personalis
May 08, 2026 BUY Strong Buy
+12.8% avg upside
11 analysts
$10.00
5.17% Downside
+76.2%
GH
Guardant Health
May 08, 2026 BUY Strong Buy
-5.9% avg upside
30 analysts
$127.00
3.72% Downside
+34.9%
PACB
Pacific Biosciences
May 08, 2026 BUY Buy
+213.7% avg upside
14 analysts
$3.00
114.27% Upside
-20.6%
QGEN
Qiagen
May 07, 2026 HOLD Buy
+14.2% avg upside
23 analysts
$40.00
8.30% Upside
-2.2%
TXG
10x Genomics
May 07, 2026 HOLD Buy
-27.9% avg upside
18 analysts
$25.00
28.03% Downside
+41.6%
NTRA
Natera
May 07, 2026 BUY Strong Buy
+7.4% avg upside
26 analysts
$280.00
21.07% Upside
+3.0%
QTRX
Quanterix
May 06, 2026 HOLD Buy
+460.5% avg upside
8 analysts
$4.00
17.92% Upside
-23.4%
WAT
Waters
May 06, 2026 HOLD Buy
+3.6% avg upside
30 analysts
$385.00
8.32% Upside
+2.1%
SERA
Sera Prognostics
May 06, 2026 BUY Strong Buy
+325.6% avg upside
7 analysts
-3.3%
ADPT
Adaptive Biotechnologies
May 06, 2026 BUY Strong Buy
+19.9% avg upside
14 analysts
$21.00
19.88% Upside
+22.0%
WGS
GeneDx Holdings
May 05, 2026 BUY Strong Buy
+35.7% avg upside
9 analysts
$55.00
6.89% Downside
+77.7%
BDSX
Biodesix
May 05, 2026 BUY Strong Buy
+92.3% avg upside
8 analysts
$30.00
78.38% Upside
-0.9%
SOPH
SOPHiA GENETICS
May 05, 2026 BUY Strong Buy
+75.8% avg upside
7 analysts
-6.5%
ILMN
Illumina
Apr 30, 2026 HOLD Buy
-10.1% avg upside
30 analysts
$140.00
13.64% Downside
+25.5%
AVTR
Avantor
Apr 29, 2026 HOLD Buy
+49.6% avg upside
26 analysts
$9.00
6.02% Downside
+20.5%
NAUT
Nautilus Biotechnolgy
Apr 28, 2026 BUY Strong Buy
+404.4% avg upside
5 analysts
-7.7%
NEO
NeoGenomics
Apr 28, 2026 BUY Strong Buy
+37.2% avg upside
17 analysts
$14.00
25.87% Upside
+23.6%
DHR
Danaher
Apr 21, 2026 BUY Strong Buy
+21.9% avg upside
45 analysts
$240.00
35.56% Upside
-8.6%
SEER
Seer
Feb 26, 2026 BUY Strong Buy
+551.3% avg upside
5 analysts
-17.3%
MYGN
Myriad Genetics
Feb 23, 2026 HOLD Hold
+313.3% avg upside
24 analysts
$7.00
54.16% Upside
-10.7%
BRKR
Bruker
Feb 13, 2026 HOLD Buy
-7.0% avg upside
22 analysts
$43.00
24.93% Downside
+50.1%
BDX
Becton Dickinson
Jul 14, 2025 HOLD Buy
+35.5% avg upside
25 analysts
$183.00
27.13% Upside
+6.0%
LAB
Standard BioTools
May 06, 2025 BUY Buy
+645.3% avg upside
8 analysts
$2.50
201.32% Upside
-8.5%
LULU
Lululemon Athletica
Apr 27, 2023 BUY Buy
+90.2% avg upside
45 analysts
$525.00
369.73% Upside
-3.5%
VZ
Verizon
Apr 26, 2023 BUY Strong Buy
+11.3% avg upside
39 analysts
$45.00
0.87% Downside
+15.5%
MRVI
Maravai Lifesciences Holdings
Oct 15, 2021 BUY Strong Buy
+174.4% avg upside
17 analysts
$62.00
1092.38% Upside
-48.0%
TWST
Twist Bioscience
Oct 14, 2021 BUY Strong Buy
-26.4% avg upside
14 analysts
-75.0%
CRL
Charles River Labs
Aug 17, 2021 BUY Strong Buy
+11.9% avg upside
34 analysts
$465.00
151.39% Upside
-47.3%
MTD
Mettler-Toledo
May 07, 2021 SELL Buy
+2.7% avg upside
18 analysts
$1139.00
0.54% Downside
-2.9%
IQV
IQVIA Holdings
Apr 23, 2021 BUY Strong Buy
+34.5% avg upside
38 analysts
$275.00
63.98% Upside
-1.8%
ICLR
Icon
Mar 01, 2021 BUY Strong Buy
+23.8% avg upside
25 analysts
$232.00
59.00% Upside
+33.7%
VCYT
Veracyte
Nov 26, 2013 BUY Strong Buy
-20.7% avg upside
17 analysts
$16.00
70.22% Downside
-48.4%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Daniel Brennan — Frequently Asked Questions
How accurate are Daniel Brennan's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Daniel's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, or -196.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Daniel ranked on 13Foresight?
Daniel Brennan is currently ranked #2165 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on RVTY, TEM, GRAL, A, TMO, MDXH, ALMR, XGN, CAI, PSNL, GH, PACB and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.